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Abstract: Human Campylobacter-infections are progressively rising globally. However, the molecular
mechanisms underlying C. coli–host interactions are incompletely understood. In this study, we surveyed
the impact of the host-specific intestinal microbiota composition during peroral C. coli infection applying
an established murine campylobacteriosis model. Therefore, microbiota-depleted IL-10−/− mice were
subjected to peroral fecal microbiota transplantation from murine versus human donors and infected
with C. coli one week later by gavage. Irrespective of the microbiota, C. coli stably colonized the
murine gastrointestinal tract until day 21 post-infection. Throughout the survey, C. coli-infected
mice with a human intestinal microbiota displayed more frequently fecal blood as their murine
counterparts. Intestinal inflammatory sequelae of C. coli-infection could exclusively be observed in
mice with a human intestinal microbiota, as indicated by increased colonic numbers of apoptotic
epithelial cells and innate as well as adaptive immune cell subsets, which were accompanied by more
pronounced pro-inflammatory cytokine secretion in the colon and mesenteric lymph nodes versus
mock controls. However, in extra-intestinal, including systemic compartments, pro-inflammatory
responses upon pathogen challenge could be assessed in mice with either microbiota. In conclusion,
the host-specific intestinal microbiota composition has a profound effect on intestinal and systemic
pro-inflammatory immune responses during C. coli infection.
Keywords: Campylobacter coli; campylobacteriosis model; host–pathogen interaction; microbiota-depleted
IL-10−/− mice; intestinal immunopathology; bacterial colonization capacity; host-specific intestinal
microbiota; fecal microbiota transplantation; colonization resistance
1. Introduction
Campylobacter infections represent frequent causes of human enteritis with rising
prevalence worldwide. The majority of campylobacteriosis cases are attributed to Campylobacter jejuni
and Campylobacter coli [1,2], and pathogen-induced clinical symptoms are characterized by
watery or bloody, inflammatory diarrhea, abdominal pain, and fever [3,4]. While Campylobacter
infections are usually self-limiting and mostly require symptomatic treatment, antimicrobial
interventions are only recommended in severe cases, particularly in immuno-compromised
individuals [4,5]. In rare cases, primary campylobacteriosis triggers long-term post-infectious sequelae,
such as Guillain-Barré syndrome, reactive arthritis, and chronic inflammatory intestinal illnesses,
including coeliac disease, irritable bowel syndrome, and chronic inflammatory bowel diseases [4–6].
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Campylobacter are present in both urban and agricultural environments, and have been isolated
from water sources and from intestinal contents of vertebrates including wild birds and mammals [7–9].
The main mode of human Campylobacter infections is ingestion of contaminated water, milk and
undercooked meat derived from livestock, mostly chickens and other poultry. Given that the bacteria
are part of the commensal gastrointestinal microbiota [5,10], C. jejuni and C. coli share the same reservoirs,
while the prevalence amongst species varies. C. coli, for instance, have been found in swine and sheep
at high frequencies [9,11,12].
Given that C. coli infections far less frequently cause human enteritis than C. jejuni [13],
Campylobacter research has been focused mostly on the latter. Therefore, our knowledge regarding
the molecular mechanisms of C. coli–host interactions is very limited. However, the burdens that
C. coli infections cause to the public health and the socioeconomic systems worldwide should not
be underscored. In fact, depending on the geographical location, C. coli are responsible for up to 25%
of reported campylobacteriosis cases [14].
Detailed analyses of the molecular mechanisms underlying the immunopathogenesis of
campylobacteriosis have been hampered by the lack of appropriate experimental infection and
inflammation models. Particularly, conventional laboratory mice can hardly be infected by C. jejuni
due to the colonization resistance that is caused by the mouse-specific intestinal microbiota composition,
preventing the murine host from invading pathogens [15,16]. Therefore, researchers successfully
abrogated the colonization resistance by antibiotic treatment of mice [16–18]. Upon peroral
C. jejuni infection, microbiota depleted wildtype mice were effectively colonized by the pathogens but
did not develop overt clinical signs of intestinal inflammation due to their resistance to pathogenic
lipooligosaccharide (LOS), constituting a major pathogenicity factor of Campylobacter [19]. The recent
progress that has been made in overcoming these fundamental obstacles in Campylobacter research is
based upon the modification of the host-specific intestinal microbiota composition and sensitization
of the murine host to C. jejuni-LOS by genetic or dietary modulations [19]. We and others have
applied microbiota-depleted interleukin-10-deficient (IL-10−/−) mice, for instance, that develop
C. jejuni-induced intestinal inflammation resembling clinical and immunopathological key features of
human campylobacteriosis [16,20–22].
Our recent research provided further evidence that the host-specific intestinal microbiota
composition plays a pivotal role in the resistance of mice against C. jejuni colonization since C. jejuni was
able to establish in the gastrointestinal tract of mice with a human intestinal microbiota, whereas mice
with a murine intestinal microbiota were completely protected from pathogenic infection [16,23].
In order to extend these findings to C. coli, we have previously surveyed the gastrointestinal
colonization properties of C. coli in conventional wildtype mice. Following peroral infection with a
C. coli strain that had been isolated from a human patient presenting with bloody diarrhea, the bacteria
were able to colonize the gastrointestinal tract of mice with a conventional intestinal microbiota until
day 21 post-challenge, which was, however, not the case when perorally applying the closely related
C. jejuni bacteria [24]. This complete absence of the physiological colonization resistance against C. coli
in conventional mice prompted us in our actual study to further unravel the triangle relationship
(“ménage-à-trois”) between the pathogen, the vertebrate host immunity, and the intestinal microbiota of
murine versus human origin in a clinical acute campylobacteriosis model by using microbiota-depleted
IL-10−/− mice.
2. Results
2.1. Association of Microbiota-Depleted IL-10−/− Mice with a Murine or Human Fecal Microbiota Prior
C. coli Infection
In order to assess the impact of the host-specific intestinal microbiota on C. coli infection and
subsequent inflammatory responses, microbiota-depleted IL-10−/− mice were perorally subjected to
fecal microbiota transplantations (FMT) from human or murine donors on three occasions (namely,
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days -7, -6, and -5; Supplementary Figure S1). Cultural as well as culture-independent (i.e., 16S
rRNA-based) analyses of the main intestinal bacterial groups abundant in the fecal donor suspensions
revealed distinct host-specific differences in microbiota composition as indicated by higher loads of
enterobacteria, enterococci, bifidobacteria, Bacteroides/Prevotella species (spp.)., Clostridium leptum, and
Clostridium coccoides groups, but lower lactobacilli and Mouse Intestinal Bacteroides counts in human
versus murine donor suspensions (p < 0.05–0.001; Figure 1).
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Figure 1. Bacterial composition of human and murine donor suspensions used for fecal microbiota
transplantation. Immediately before fecal microbiota transplantations on three consecutive days
(i.e., days -7, -6, -5), the bacterial compositions of respective donor suspensions derived from murine
(M; open circles) or human (H; closed circles) donors were quantitatively assessed by (A) culture and (B)
culture-independent 16S rRNA-based methods and expressed as colony forming units per ml (CFU/mL)
and copies/ng DNA, respectively. Medians (black bars) and significance levels (p-values) assessed by
the M nn–Whitney U test are i dicated. Data wer pooled from two independent xperiments.
TL: total bacterial load; EB: enterobacteria; EC: enterococci; LB: lact bacilli; BB: ifidobacteria;
BP: Bacteroides/P evotella species; MIB: M use Intestinal Bacteroides; CE: Clostridium/Eubacterium species;
CL: Clostridium leptum group; CC: Clostridium coccoides group (n = 6).
Immediately before the first of two peroral C. coli infections on days 0 and 1, the bacterial
colonization efficacies following FMT that had been started 7 days before was quantitatively assessed
again by culture and culture-independent analyses. Like in case of the bacterial donor suspensions,
pronounced host-specific differences in fecal microbiota compositions could be observed as indicated
by higher total eubacterial loads and by higher numbers of enterobacteria, enterococci, bifidobacteria,
Bacteroides/Prevotella spp., Clostridium leptum, and Clostridium coccoides groups in human as compared to
mouse microbiota-associated mice (p < 0.05–0.001), whereas lactobacilli and Mouse Intestinal Bacteroides
loads were lower in the former versus the latter (p < 0.001; Figure 2). Hence, distinct host-specific
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differences in the intestinal microbiota composition could be assessed immediately before C. coli
infection of secondary abiotic IL-10−/− mice that had been challenged with human or murine FMT.
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Figure 2. Intestinal microbiota composition of microbiota-depleted IL-10−/− mice that had been
challenged with human or murine microbiota transplantations immediately before C. coli infection.
Immediately before C. coli infection (i.e., day (d) 0), and seven days after the first of three consecutive
murine (M; open circles) versus human (H; closed circles) fecal microbiota transplantations, the fecal
microbiota composition was quantitatively assessed by (A) culture and (B) culture-independent 16S
rRNA-based (molecular) methods and expressed as colony for ing units per ml (CFU/mL) and
copies/ng DNA, respectively. Medians (blac ars) and significance levels (p-values) assessed by
the Mann–Whitney test are indicated. Data wer pooled f om four i dep ndent experiments.
TL: tot l bacterial load; EB: enterob cteria; EC: enterococci; LB: lactobacilli; BB: bifidobacteria;
BP: Bacteroides/Prevotella species; I : ouse Intestinal Bacteroides; CE: Clostridium/Eubacterium species;
CL: Clostridium leptum group; CC: Clostridium coccoides group (n = 31).
2.2. Fecal Pathogen Shedding after Oral C. coli Infection of icr i t - epleted IL-10−/− Mice th t Had Been
Subjected to Human or Murine Fecal Microbi ta Transplantations
We then performed a kinetic survey of the fecal pathogen loads following peroral infection
with 108 viable C. coli that had been derived from a patient presenting with bloody diarrhea on
two consecutive days (i.e., on days 0 and 1; Supplementary Figure S1) by gavage. Regardless of
whether the mice had been subjected to human or murine FMT, C. coli could stably establish within
the intestinal tract until the end of the survey (namely, 21 days post-infection (p.i.)) with median
loads of approximately 108 colony forming units (CFU) per g feces (Figure 3). As early as 48 h after
the latest C. coli infection, pathogen loads were slightly higher in human versus murine intestinal
microbiota-associated mice (p < 0.001; Figure 3). Furthermore, in mice that had been challenged with a
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human fecal microbiota, C. coli loads decreased by less than two log orders from day 3 till day 21 p.i.
(p < 0.001; Figure 3).
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Figure 3. Fecal C. coli shedding over time upon oral infection of microbiota-depleted IL-10−/− mice
that had been challenged with human or murine fecal microbiota transplantations. On days -7, -6,
and -5, mice were subj ted to urine (M; open circles) or human (H; clos d circles) fecal microbiota
transplantations. On days 0 and 1, micro i ta-associated mice were then perorally infected with a
C. coli patient isolate and fecal bacterial loads were quantitated in each mouse over time post-infection
by culture (expressed as colony forming units per g; CFU/g). Medians (black bars), significance levels
(p-values calculated by the Kruskal–Wallis test and Dunn’s post-correction and by the Mann–Whitney
U test comparing C. coli loads in mice following murine versus um n FMT at identical time points
post-infection) and numbers of culture-positive animals out of the total number of mice under
investigation (in parentheses) are indicated. Results from four experiments were pooled.
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Figure 4. Gastrointe tinal C. coli loads upon oral inf tion of micr biota-d pleted IL-10−/− mice that
had been challenged with human or murine fecal icrobiota transplantations. On days -7, -6, and -5,
mice were subjected to murine (M; open symbols) or human (H; closed circles) fecal microbiota
transplantations. On day 21 following peroral infection with a C. coli patient isolate on day 0 and
day 1, the pathogen burdens were quantitated in gastrointestinal compartments applying culture and
expressed as col ny forming units per g (CFU/g). Nu bers of culture-positive animals out of the
total number of mice under investigation (in parentheses) and medians (black bars) are indicated.
Results from four experiments were pooled.
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Upon necropsy on day 21 p.i., we quantitated C. coli alongside the gastrointestinal tract
(namely, the stomach, duodenum, ileum, and colon) and observed (from the intestinal microbiota
composition independent) comparable loads in respective compartments with highest counts in the
large intestines (Figure 4). Hence, C. coli was able to establish within the gastrointestinal tract of
microbiota-depleted mice that had been challenged with human or murine FMT.
2.3. Kinetic Assessment of Clinical Conditions Following Peroral C. coli Infection of Microbiota-Depleted
IL-10−/− Mice That Had Been Subjected to Human or Murine Fecal Microbiota Transplantations
We next surveyed the clinical conditions over time post-pathogen challenge by a standardized
clinical scoring system quantitatively assessing wasting, stool consistency, and the occurrence of fecal
blood (Supplementary Figure S2). At days 7 and 21 following C. coli infection, mice harboring a human,
but not murine intestinal microbiota displayed higher clinical scores as compared to time points prior
to infection (i.e., days -7 and 0; p < 0.01; Supplementary Figure S2D), whereas at the end of the survey,
44.4% and 35.3% of infected mice with a human and murine microbiota respectively, displayed any
C. coli-induced clinical signs (Supplementary Figure S1B,D). Mice from respective mock cohorts,
however, were clinically uncompromised (Supplementary Figure S2A,C).Pathogens 2020, 9, x FOR PEER REVIEW 7 of 19 
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Figure 5. Occurrence of fecal blood over time following C. coli infection of microbiota-depleted
IL-10−/− mice that had been challenged with human or murine fecal microbiota transplantations.
On days -7, -6, and -5, mice were subjected to murine or human fecal microbiota transplantation (FMT)
and challenged with a C. coli p t isolate (closed bars; (B)) or vehicle as m ck controls (open bars; (A))
on days 0 and 1 by gavage. Bars indicate the lative frequencies of fecal blood a assessed by the
Guajak method (in %). Numbers of fecal blood-positive animals out of the total number of mice under
investigation are given (in parentheses). Results from four experiments were pooled.
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When assessing the occurrence of blood in fecal samples (Figure 5), 61.1% of mice harboring
a human intestinal microbiota, but only 5.9% from the murine microbiota cohort, displayed fecal blood
on day 7 p.i., whereas later on, on day 21 p.i., respective fecal blood positivity rates were 44.4% and
35.3% in the former as compared to the latter (Figure 5B). In none of the mock control mice any fecal
blood was detected at days 7 and 21 p.i. (Figure 5A). Hence, particularly during the early phase of
C. coli infection, mice harboring a human as opposed to a murine intestinal microbiota displayed
fecal blood.
2.4. Intestinal Histopathological, Apoptotic, and Pro-Inflammatory Immune Responses upon Peroral C. coli
Infection of Microbiota-Depleted IL-10−/− Mice That Had Been Subjected to Human or Murine Fecal
Microbiota Transplantations
We next quantitated large intestinal histopathological changes using an established
histopathological scoring system [25]. At day 21 following C. coli infection of human or murine intestinal
microbiota-associated mice, higher histopathological scores could be determined as compared to
respective mock control animals (p < 0.01 and p < 0.001, respectively) which were higher in the former
versus the latter (p < 0.01; Figure 6A). Since apoptosis is considered another valuable marker for
inflammatory responses in the intestinal tract [16], we quantitated cleaved caspase3+ cell numbers in
colonic epithelia by in situ immunohistochemistry. At day 21 following C. coli infection, mice with
a human, but not a murine intestinal microbiota, displayed elevated numbers of apoptotic colonic
epithelial cells as compared to respective mock control counterparts (p < 0.01 versus mock; Figure 6B
and Supplementary Figure S3B), whereas Ki67+ cells counts indicative for cell proliferation/regeneration
were comparable in respective groups (not significant (n.s.); Figure 6C and Supplementary Figure S3C).
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Figure 6. Colonic histopathological, epithelial apoptotic, and proliferative cell responses upon oral C. coli
infection of microbiota-depleted IL-10−/− mice that had been challenged with human or murine fecal
microbiota transplantations. On days (d) -7, -6, and -5, mice were subjected to murine (open symbols)
or human (closed symbols) fecal microbiota transplantations and challenged with a C. coli patient
isolate (circles) or vehicle as mock controls (diamonds) on days 0 and 1 by gavage. On day 21
post-infection, (A) histopathological changes were quantitated in large intestinal paraffin sections
according to a standardized histopathological scoring protocol. Furthermore, the average numbers of
(B) apoptotic (Casp3+) and (C) proliferating (Ki67+) cells were determined in colonic epithelia out of
6 high-power fields (HPF, 400×magnification) per mouse. Medians (black bars), significance levels
(p-values calculated by the Kruskal–Wallis test and Dunn’s post-correction), and total numbers of mice
under investigation (in parentheses) are shown. Results from four experiments were pooled.
We further surveyed innate as well as adaptive immune cell responses in the large intestines
following C. coli infection, ag in by quantit tive n s tu immunohistochemical analyses of colonic
paraffi sections. Like the poptotic epithelial cell counts, C. coli nfe tion of mice with a human,
but not with a murine intestinal microbiota, was paralleled by elevated numbers of F4/80+ macrophages
and monocytes, of CD3+ T ly ph cytes, of FOXP3+ r gulatory T cells, and of B220+ B ly ph cytes in
Pathogens 2020, 9, 804 8 of 18
the colonic mucosa and lamina propria versus mock controls at day 21 p.i. (p < 0.001; Figure 7 and
Supplementary Figure S3D–G).
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transplantat ons and challenged with a C. coli patient isolate (cir les) or vehic e as mock controls
(diamonds) d ys 0 nd 1 by gavage. On day 21 p st-infection, the average numbers of (A)
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and (D) B lymphocytes (B220+) were determined in the large intestinal mucosa and lamina propria out
of 6 high-power fields (HPF, 400x magnification) per mouse. Medians (black b rs), signific nce levels
(p-values calculated by the Kruskal–Wallis test and Dunn’s p st-correctio ), and total numbers of mice
under investigation (in parent ses) are shown. Results from four experiments were p oled.
Next, we determined pro-inflammatory cytokine secretion in distinct compartments of the
intestinal tract. A day 21 post-C. coli infection, only mic harbor g a human intestinal microbiota
displayed higher tumor necrosis fa tor (TNF)-α concentrations in ex vivo biops es derived from c lon
and mesenteric lymph nodes (MLN) d aining the inflamed intestin s as compared to mock counterparts
(p < 0.001; Figure 8A,C), which also held true for int rferon (IFN)-γ measured in the MLN (p < 0.05;
Figure 8D). Hence, C. coli infection of mice with a human, b t n t murine, i testinal microbiota induced
apoptotic cell and pro-inflammatory immune responses within the intestinal tract.
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microbiota transplantations. On days -7, -6, and -5, mice were subjected to murine (open symbols)
or human (closed symbols) fecal microbiota transplantations and challenged with a C. coli patient
isolate (circles) or vehicle as mock controls (diamonds) on days 0 and 1 by gavage. On day 21
post-infection, TNF-α (A,C) and IFN-γ (B,D) concentrations were determined in supernatants of ex vivo
biopsies derived from colon (A,B) and mesenteric lymph nodes (MLN; (C,D)). Medians (black bars),
significance levels (p-values calculated by the Kruskal–Wallis test and Dunn’s post-correction), and total
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2.5. Extra-Intestinal Including Systemic Pro-Inflammatory Immune Responses upon Peroral C. coli Infection of
Microbiota-Depleted IL-10−/− Mice That Had Been Subjected to Human or Murine Fecal Microbiota Transplantations
Next, we asked whether the observed C. coli-induced inflammatory effects in mice with a
human intestinal microbiota were restricted to the intestinal tract or also effective in extra-intestinal,
including systemic, compartments. At day 21 p.i., increased TNF-α concentration could be assessed in
liver and kidneys of mice with a murine, but not human, intestinal microbiota (p < 0.05–0.01 vs. mock;
Figure 9A,C,D), whereas pathogen-induced increases in hepatic IFN-γ concentrations were from the
microbiota independent (p < 0.001 vs. mock; Figure 9B).
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In the systemic compartment, C. coli-induced inflammatory sequelae could be assessed in mice
with either microbiota composition: Whereas, at day 21 p.i., increased TNF-α concentrations could
only be measured in seru samples taken from human microbiota-associated mice (p < 0.00 vs. mock;
Figure 10A), IFN-γ concentrations were higher in infected versus mock challenged controls of either
intestinal microbiota (p < 0.05–0.001; Figure 10B).
We further asked whether viable C. coli might have translocated from the infected intestines to
respective extra-intestinal and even systemic tissue sites. However, pathogenic cells could neither
be isolated from liver nor from kidney ex vivo biopsies. In addition, all cardiac blood samples
remained culture-negative.
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Hence, whereas in the intestinal tract inflammatory sequelae of C. coli infection could exclusively
be observed in mice with a human intestinal microbiota, extra-intestinal, including systemic,
pro-inflammatory responses upon pathogen challenge could be assessed in mice of either microbiota.
Pathogens 2020, 9, x FOR PEER REVIEW 12 of 19 
 
isolat d from liver nor from kidney ex vivo biopsies. In addition, all cardiac blood samples remained 
culture-negative. 
Hence, whereas in the intestinal tract inflammatory sequelae of C. coli infection could exclusively 
be observed in mice with a human intestinal microbiota, extra-intestinal, including systemic, pro-
inflammatory responses upon pathogen challenge could be assessed in mice of either microbiota. 
 
Figure 10. Systemic secretion of pro-inflammatory cytokines upon oral C. coli infection of microbiota-
depleted IL-10−/− mice that had been challenged with human or murine fecal microbiota 
transplantations. On days -7, -6, and -5, mice were subjected to murine (open symbols) or human 
(closed symbols) fecal microbiota transplantations and challenged with a C. coli patient isolate (circles) 
or vehicle as mock controls (diamonds) on days 0 and 1 by gavage. On day 21 post-infection, (A) TNF-
α and (B) IFN-γ concentrations were determined in serum samples. Medians (black bars), significance 
levels (p-values calculated by the Kruskal–Wallis test and Dunn’s post-correction), and total numbers 
of mice under investigation (in parentheses) are shown. Definite outliers were removed after 
identification by the Grubb’s test (α = 0.001). Results from four experiments were pooled. 
3. Discussion 
Based on our recent findings that C. coli—as opposed to C. jejuni—are able to overcome the 
physiological colonization resistance of mice exerted by the murine intestinal microbiota 
composition, and therefore, can stably establish within the gastrointestinal tract of conventionally 
colonized wildtype mice [24], here, for the first time, we addressed whether the host-specific human 
as compared to murine microbiota composition impacts the outcome of campylobacteriosis induced 
by C. coli in microbiota-depleted IL-10−/− mice representing a reliable clinical experimental model for 
C. jejuni infection and induced inflammation [19]. During the entire observation period (i.e., 21 days) 
after C. coli infection of IL-10−/− mice that had been re-associated with a murine or human intestinal 
microbiota upon peroral FMT, comparable pathogen loads could be determined in the intestinal tract. 
One could argue that the respective fecal donor microbiota might not have fully established in the 
murine host. Our cultural analyses and culture-independent molecular approaches additionally 
assessing fastidious and non-cultivable bacteria revealed, however, that the host-specific differences 
in numbers of the most common intestinal bacterial groups, genera, and species between respective 
fecal donor suspensions could also be observed in the intestinal tract of IL-10−/− mice after 
establishment of the complex human versus murine intestinal microbiota following peroral FMT. 
Even though the methods applied here have their limitations regarding the possibilities to provide a 
complete picture of the commensal ecological conditions within the gut lumen, the combinatory 
approach of quantitative “culturomics” plus 16S rRNA-based analyses have been proven highly 
reliable for a comprehensive survey of differences in host-specific intestinal microbiota compositions 
Figure 10. Systemic secretion of pro-inflammatory cytokines upon oral C. coli infection of
microbiota-depleted IL-10−/− mice that had been challenged with human or murine fecal
microbiota transplantations. On days -7, -6, and -5, mice were subjected to murine (open symbols) or
human (closed symbols) fecal microbiota transplantations and challenged with a C. coli patient isolate
(circles) or vehicle as mock controls (diamonds) on days 0 and 1 by gavage. On day 21 post-infection,
(A) TNF-α and (B) IFN-γ concentrations were determined in serum samples. Medians (black bars),
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numbers of mice under investigation (in parentheses) are shown. Definite outliers were removed after
identification by the Grubb’s test (α = 0.001). Results fr m four experiments were pooled.
3. Discussion
Based on our recent findings that C. coli—as opposed to C. jejuni—are able to overcome the
physiological colonization resistance of mice exerted by the murine intestinal microbiota composition,
and therefore, can stably establish within the gastrointestinal tract of conventionally colonized
wildtype mice [24], here, for the first time, we addressed whether the host-specific human as
compared to murine microbiota composition impacts the outcome of campylobacteriosis induced by
C. coli in microbiota-depleted IL-10−/− mice representing a reliable clinical experimental mo el for
C. jejuni infection and induced inflammation [19]. During the entire observation period (i.e., 21 days)
after C. coli infection of IL-10−/− mice that had been re-associated with a murine or human intestinal
microbiota upon peroral FMT, comparable pathogen loads coul be deter ined in t e intestinal tract.
One could argue that the respective fecal donor microbiota might not have fully established in the
murine host. Our cultural analyses and culture-independent molecular approaches additio ally
assessing fastidious and non-cultivable bacteria revealed, however, that the host-specific differences in
numbers of the most common intestinal bacterial groups, genera, and species between respective fecal
do or suspensions c uld also be observed in the intestinal tract of IL-10−/− mice after establishment
of the c mplex human versus murine intestinal microbiota following peroral FMT. Even though the
methods applied here have their li itations regarding the possibilities to provide a complete picture of
the commensal ecological conditions within the gut lumen, the combi atory approach of quantitative
“culturomics” plus 16S rRNA-based analyses have been proven hig ly reliable for a comprehensive
survey of differe ces in host-specific intestinal microbiota compositions [15,16,24,26–34]. O e needs
to take into account, however, that during processi g f the fecal donor samples, including freezi g
and thawing, individual bacterial strains might have been reduced and not fully established within
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the intestinal tract upon FMT [27,30,35]. Nevertheless, it is rather the gut luminal milieu provided
by the orchestrated interplay between the vast majority of the complex intestinal microbiota than by
individual players accounting for the host-specific differences of biological impact. Therefore, it would
be utmost appreciable in future studies to assess differences in the intraluminal milieu by metabolomic
and/or proteomic approaches, for instance, in order to obtain further insights into the underlying
molecular mechanisms of pathogen–host interactions.
Despite comparable intestinal C. coli loads in mice harboring a human versus a murine
intestinal microbiota, pathogen-induced clinical signs such as fecal blood could more frequently
be observed in the former as compared to the latter, especially during the early phase of infection.
Moreover, the host microbiota-dependent differences in C. coli-induced sequelae were also true on the
microscopic level given that only mice harboring a human as opposed to a murine microbiota presented
with (i) pronounced colonic epithelial apoptosis, (ii) higher numbers of recruited innate and adaptive
immune cells in their large intestinal mucosa and lamina propria, and (iii) an enhanced secretion of
pro-inflammatory cytokines such as TNF-α in the colon and MLN draining the infected intestines.
The attempt to correlate the observed microbiota-dependent effects during C. coli infection with distinct
bacterial species appears to be challenging, and, literally, rather a search for the needle in the haystack.
However, when comparing both the donor suspensions of human and murine origin and the fecal
samples derived from human and murine intestinal microbiota-associated mice, the former contained
higher enterobacterial loads as compared to the latter, for instance. Our previous studies revealed that
acute as well as chronic inflammatory conditions within the intestinal tract of different etiologies are
accompanied by an overgrowth of the inflamed gut lumen with enterobacterial commensals including
Escherichia coli, which are involved in the initiation and also the exacerbation of the inflammatory
immune responses in a Toll-like receptor-4 (TLR-4)-dependent fashion [34,36–43]. It is thus tempting
to speculate that interactions (the “crosstalk”) between C. coli on the pathogen side and Gram-negative
species such as Escherichia coli on the commensal gut bacterial side might be responsible for the observed
sequelae of C. coli infection in IL-10−/− mice harboring a human intestinal microbiota [44].
Interestingly, whereas in the intestinal tract, inflammatory sequelae of C. coli infection
were exclusively observed in mice harboring a human intestinal microbiota, extra-intestinal,
including systemic, pro-inflammatory responses upon pathogen challenge could be assessed in
mice of either microbiota. To further unravel these rather unexpected results, we assessed whether
viable C. coli might have translocated from the gastrointestinal tract to extra-intestinal and systemic
tissue sites, but were unable to isolate any bacteria from liver, kidneys, and blood. Nevertheless,
soluble cell wall constituents such as C. coli-LOS might have translocated to respective compartments,
resulting in the observed inflammatory immune responses.
In summary, our present study revealed that peroral C. coli infection results in pronounced
clinical signs, apoptotic, and pro-inflammatory immune responses in the intestinal tract of IL-10−/−
mice harboring a human intestinal microbiota, whereas IL-10−/− mice with a murine intestinal
microbiota were stably colonized by the pathogen, but protected from disease manifestations.
Given that murine FMT treatment could effectively dampen pathogen-induced apoptotic epithelial and
pro-inflammatory immune responses in the large intestines of C. jejuni-infected microbiota-depleted,
as well as of “humanized”, IL-10−/− mice [27,31], these findings collectively provide strong evidence
that microbiota modifications by pre- or probiotics, for instance, might open novel avenues for future
treatment strategies in the combat of campylobacteriosis in humans.
4. Materials and Methods
4.1. Ethics Statement
All mouse experiments were performed in accordance to the European Guidelines for animal
welfare (2010/63/EU) after being approved by the commission for animal experiments (“Landesamt für
Pathogens 2020, 9, 804 13 of 18
Gesundheit und Soziales”, LaGeSo, Berlin, registration number G0247/16). The clinical conditions of
animals were assessed twice a day.
4.2. Generation of Microbiota-Depleted Mice
IL-10−/−mice with a C57BL/6J background were bred and maintained under specific pathogen-free
conditions in the identical unit of the Forschungseinrichtungen für Experimentelle Medizin
(Charité-University Medicine Berlin). Under standard conditions (i.e., 22–24 ◦C temperature, 55% ± 15%
humidity, 12 h light/12 h dark cycle), animals were kept in cages with filter tops within an experimental
semi-barrier. Mice had access to autoclaved water and chow (food pellets: ssniff R/M-H, V1534-300,
Sniff, Soest, Germany) ad libitum. To overcome physiological colonization resistance, mice were
treated with broad-spectrum antibiotic compounds rendering them secondary abiotic, as described
earlier [16,36]. Briefly, immediately after weaning, 3-week-old mice were treated with an antibiotic
cocktail consisting of ampicillin plus sulbactam (1 g/L; Dr. Friedrich Eberth Arzneimittel, Ursensollen,
Germany), vancomycin (500 mg/L; Hikma Pharmaceuticals, London, UK), ciprofloxacin (200 mg/L;
Fresenius Kabi, Bad Homburg, Germany), imipenem (250 mg/L; Fresenius Kabi), and metronidazole
(1 g/L; B. Braun, Melsungen, Germany) dissolved in autoclaved drinking water (ad libitum) [36].
To ensure antimicrobial washout, the antibiotic cocktail was withdrawn and replaced by autoclaved
water three days prior to the initial FMT.
4.3. Fecal Microbiota Transplantations
On days -7, -6, and -5, sex- and age-matched microbiota-depleted IL-10−/− mice
(three-month-old littermates) were perorally subjected to peroral murine or human FMT by gavage,
as described earlier in more detail [16,29,30,35,45]. Briefly, fecal samples (lacking enteropathogenic
parasites, viruses, and bacteria) were derived from five healthy human donors or from 3-month-old
C57BL/6 mice (3 female, 2 male murine donors), suspended in phosphate buffered saline (PBS; Thermo
Fisher Scientific, Waltham, MA, USA), and aliquots stored at −80 ◦C. For FMT, respective fecal aliquots
were thawed, pooled, and applied to mice by gavage (total volume of 0.3 mL). For stable establishment
of the human and murine intestinal microbiota in the gastrointestinal tract of the murine host, the C. coli
challenge started one week post-FMT.
4.4. C. coli Infection, Colonisation Properties, and Translocation
The used C. coli strain had been isolated from a patient with bloody diarrhea (kindly provided by
Dr. Torsten Semmler, Robert-Koch-Institute Berlin, Berlin, Germany). Mice were perorally challenged
with 108 C. coli cells by gavage (in 0.3 mL PBS) on days 0 and 1, as stated earlier [24,44].
To assess gastrointestinal colonization properties, C. coli were enumerated in fecal samples at
distinct time points post-infection by culture and additionally in gastrointestinal luminal samples
including colon, ileum, duodenum, and stomach on the day of sacrifice, as reported previously [24,44].
Briefly, serial dilutions of fecal samples were plated on Karmali agar plates and on Columbia agar
plates containing 5% sheep blood (Oxoid, Wesel, Germany) and incubated under microaerophilic
conditions in a jar for 48 h at 37 ◦C. For assessing bacterial translocation, ex vivo biopsies taken from
the kidneys, liver, and MLN were homogenized in sterile PBS and cultivated on respective agar plates,
whereas C. coli were isolated from cardiac blood [24,44]. The C. coli detection limit was ≈100 CFU/g.
4.5. Analyses of the Intestinal Microbiota Composition
In order to quantitatively assess the microbiota composition in fecal human and murine
donor suspensions and colonic luminal contents, samples were homogenized in sterile PBS
and enumerated from serial dilutions on respective solid media and grown at 37 ◦C for at
least two days under aerobic, microaerobic, and anaerobic conditions, as described earlier [37].
For culture-independent (molecular) intestinal microbiota analysis, the total genomic DNA was
extracted from the donor suspensions and colonic luminal samples as reported earlier [37]. The main
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bacterial groups within the human and murine intestinal microbiota were surveyed by quantitative
real-time polymerase chain reaction (qRT-PCR) with species-, genera-, or group-specific 16S rRNA
gene primers (Tib MolBiol, Berlin, Germany), as described previously [45,46].
4.6. Clinical Conditions
Before initial FMT and C. coli challenge as well as after bacterial infections, the clinical status of
mice was surveyed applying a standardized, cumulative clinical scoring system (maximum 12 points),
which took into account the overall clinical aspects (0: normal; 1: ruffled fur; 2: less locomotion;
3: isolation; 4: severely compromised locomotion, wasting, pre-final aspect), the occurrence of blood
in feces (0: no blood; 2: microscopic detection of blood by the Guajac method using Haemoccult,
Beckman Coulter/PCD, Germany; 4: macroscopic blood visible), and diarrhea (0: formed feces;
2: pasty feces; 4: liquid feces), as described previously [47]. The fecal blood positivity rate was
calculated by dividing the number of macroscopically and/or microscopically fecal blood-positive mice
by the total number of analyzed mice.
4.7. Sampling Process
On day 21 p.i., mice were sacrificed by CO2 asphyxiation. Ex vivo biopsies were taken under
sterile conditions from liver, kidneys, MLN, and colon, in addition to luminal gastrointestinal samples
from the stomach, duodenum, ileum, and colon. Blood was collected by heart puncture. Samples were
taken from each mouse for microbiological, immunohistopathological, and immunological analyses
in parallel.
4.8. Histopathology and Immunohistochemistry
Histopathological analyses were performed in colonic ex vivo biopsies that had been immediately
fixed in 5% formalin and embedded in paraffin. Sections (5 µm) were stained with hematoxylin and
eosin (H&E), examined by light microscopy (100×magnification), and histopathological changes in
the large intestines were quantitatively assessed applying an established histopathological scoring
system as reported previously [25]: Score 1: minimal inflammatory cell infiltrates in the mucosa with
intact epithelium, Score 2: mild inflammatory cell infiltrates in the mucosa and submucosa with mild
hyperplasia and mild goblet cell loss, Score 3: moderate inflammatory cell infiltrates in the mucosa
with moderate goblet cell loss, and Score 4: marked inflammatory cell infiltration into in the mucosa
and submucosa with marked goblet cell loss, multiple crypt abscesses, and crypt loss.
4.9. Immunohistochemistry
In situ immunohistochemical analyses were carried out in colonic ex vivo biopsies
immediately fixed in 5% formalin and embedded in paraffin, as previously described [41,48–50].
For detection of apoptotic and proliferating epitshelial cells, macrophages/monocytes, T lymphocytes,
regulatory T cells, and B lymphocytes, 5 µm thin colonic paraffin sections were stained with primary
antibodies directed against cleaved caspase 3 (Asp175, Cell Signaling, Beverly, MA, USA, 1:200),
Ki67 (TEC3, Dako, Glostrup, Denmark, 1:100), F4/80 (# 14-4801, clone BM8, eBioscience, San Diego,
CA, USA, 1:50), CD3 (#N1580, Dako, 1:10), FOXP3 (clone FJK-165, #14-5773, eBioscience, 1:100),
and B220 (No. 14-0452-81, eBioscience; 1:200), respectively. Positively stained cells were enumerated
using light microscopy, and the average number within at least 6 high-power fields (HPF, 0.287 mm2,
400×magnification) was recorded by an unbiased investigator.
4.10. Pro-Inflammatory Mediator Measurements in Intestinal, Extra-Intestinal, and Systemic Compartments
Colonic explants were cut longitudinally, rinsed in PBS, and strips of ≈1 cm2 tissue and ex vivo
biopsies taken from liver (approximately 1 cm3), kidney (one half), and MLN (3 lymph nodes)
were placed into 24 flat-bottom-well culture plates (Thermo Fisher Scientific, Waltham, MA, USA)
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supplemented with 500 µL serum-free RPMI 1640 medium (Thermo Fisher Scientific,
Waltham, MA, USA) as well as penicillin (100 U/mL) plus streptomycin (100 µg/mL;
Biochrom, Berlin, Germany). After incubation for 18 h at 37 ◦C, respective culture supernatants
as well as serum samples were tested for TNF-α and IFN-γ by the Mouse Inflammation Cytometric
Bead Array (CBA; BD Biosciences, Heidelberg, Germany) on a BD FACSCanto II flow cytometer
(BD Biosciences, Heidelberg, Germany).
4.11. Statistical Analysis
Medians and levels of significance were calculated utilizing the Mann–Whitney test
(GraphPad Prism v8, San Diego, CA, USA) for pairwise comparisons of not normally distributed data,
and using the Kruskal–Wallis test with Dunn’s post-correction for multiple comparisons, as indicated.
Two-sided probability (p) values≤ 0.05 were considered significant. Definite outliers were removed after
being identified by the Grubb’s test (α = 0.001). Data were pooled from four independent experiments.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/9/10/804/s1,
Figure S1: Experimental set-up. Figure S2: Kinetic survey of overall clinical conditions following peroral
C. coli challenge of microbiota-depleted IL-10−/− mice that had been subjected to murine or human fecal
microbiota transplantations. Figure S3: Representative photomicrographs depicting (A) histopathological
changes in hematoxylin and eosin (H&E)-stained colonic paraffin sections, and average numbers of (B) apoptotic
(caspase3+, Casp3+) and (C) proliferating (Ki67+) epithelial cells, of (D) macrophages and monocytes (F4/80+),
(E) T lymphocytes (CD3+), (F) regulatory T cells (FOXP3+), and (G) B lymphocytes (B220+) in the colonic mucosa
and lamina propria (from at least 6 high-power fields), as quantitatively determined in immunohistochemically
stained colonic paraffin sections (100×magnification, scale bar 100 µm).
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